Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026

Moderna shares have risen more than 600% in 2026, supported by a positive Phase 3 result for its personalized melanoma vaccine and approval of its flu vaccine, but the article argues the stock is overvalued at a $90 billion market capitalization. Wall Street’s average $123.61 price target implies about 45% downside; Moderna reported $534 million in revenue and a $2.1 billion net loss in the first six months of 2026. The author says a 12% required return would require $6.34 billion in 2032 net income, and recommends avoiding the stock at current levels.

Analysis

The key repricing risk is a category shift: a positive Phase 3 result can lift the perceived probability of Moderna becoming a repeatable oncology-platform company, but it does not yet establish launch economics, durable differentiation, or a scalable manufacturing model. The commercial read-through should therefore be discounted until recurrence-free-survival benefit, follow-up duration, safety, regulatory timing, and real-world uptake are clear. Merck shares some economics while gaining a potential extension to its Keytruda franchise; the partnership also limits Moderna’s capture of any success. For Moderna, continued losses make the time and capital required to convert pipeline value into profitable sales as important as the number of shots on goal. Watch cash runway and any change in financing plans rather than assuming dilution.

Over days to weeks, momentum and short-covering can keep MRNA elevated; an outright short immediately after a clinical breakthrough has adverse squeeze risk. Over 1–3 months, the setup depends on trial detail, regulatory milestones, and management’s commercial and spending outlook. Over 6–18 months, evidence of launch execution and additional pipeline readouts—not platform rhetoric—will determine whether the valuation can be supported. Contrarian point: the market may be assigning too little value to platform optionality, so the bearish case is valuation-sensitive, not a claim that the science failed. No trade is justified solely by the article’s price-target comparison; verify current price, options costs, cash runway, and trial data first.

Key Decisions for Investors

• Do not chase MRNA after the event-driven rally. If considering a short, wait for a failed hold of the post-results breakout or a deterioration in forward revenue/cash guidance; size modestly because further positive data could extend the squeeze.
• Watch for a defined catalyst before using MRNA puts or put spreads. Compare implied volatility and premium with the next clinical/regulatory milestones; avoid paying event-volatility prices without a clear catalyst window.
• For relative exposure, consider a small MRNA-underweight / MRK-overweight pair rather than a large outright biotech short: Merck participates in the collaboration while Moderna bears more standalone platform-execution risk. This is not a clean hedge; size for their different businesses and reassess if trial details weaken the combination’s prospects.
• Falsify the bearish valuation thesis if Moderna demonstrates a credible path to lower cash burn and profitable launches, or if subsequent trial/regulatory data materially broaden the addressable opportunity. Track trial follow-up, regulatory timing, product uptake, and cash runway at the next updates.